CK-4021586: A Novel Cardiac Myosin Inhibitor with An Alternative Mechanism of Action for the Treatment of HFpEF

A Characterization of the Nonclinical Pharmacology and Toxicology of Aficamten, a Reversible Allosteric Inhibitor of Cardiac Myosin

Fast Skeletal Muscle Troponin Activator CK-4015089 Improves Muscle Function in a FSHD Mouse Model with Muscle Weakness

Cytochrome P450 (CYP) Phenotyping of Aficamten, a Next-in-class Inhibitor of Cardiac Myosin, Using Human Liver Microsomes and Human Recombinant CYP Enzymes

Cardiac Myosin Inhibitor, CK-586, Minimally Reduces Systolic Function and Ameliorates Obstruction in Feline Hypertrophic Cardiomyopathy

In Vitro and In Vivo Pharmacokinetic Preclinical Characterization of Aficamten, a Small Molecule Cardiac Myosin Inhibitor

Pharmacokinetics, Mass Balance, Tissue Distribution, Metabolism, and Excretion of [14C]Aficamten Following Single Oral Dose Administration to Rats

Discovery of Aficamten (CK-274): Next-in-class Cardiac myosin inhibitor (CMI) for obstructive Hypertrophic Cardiomyopathy (oHCM)

Cardiac Myosin Inhibitor, CK-586, Minimally Reduces Systolic Function and Ameliorates Obstruction in Feline Hypertrophic Cardiomyopathy

Fast Skeletal Muscle Troponin Activator CK-4015089 Improves Muscle Function in a FSHD Mouse Model with Muscle Weakness